Kunming Pharmaceutical Group released its 2026 interim report, with net profit attributable to the parent company at negative 364 million yuan, swinging from profit to loss year on year. Total operating revenue was 1.643 billion yuan, down 50.97 percent from the same period last year. Net cash flow from operating activities was negative 514 million yuan, a year-on-year decline of 334.90 percent. The latest gross margin was 19.27 percent, down 20.58 percentage points from the same period last year. Diluted earnings per share were negative 0.48 yuan. The company's latest asset-liability ratio was 41.37 percent, and the number of shareholders was 52,200.
KPC Pharmaceuticals IncNet loss of 364 million yuan, revenue down 50.97%, and negative operating cash flow.
